Advising Catalent Pharma Solutions, Inc., a global listed pharmaceutical company headquartered in the U.S., in relation to the sale of 100% of its tablet and soft-gel capsule manufacturing facility in Victoria, Australia for AUD43.2 million to Blackmores Limited.
Advising on the application of the Australian Anti-Money Laundering and Counter-Terrorism Financing Act 2006 (Cth).
Assisting a foreign asset management company in obtaining ASIC registration in Australia.
Advising a global payment facility provider about the Australian regulation of non-cash payment facilities and assisting it to respond to inquiries from ASIC.
Advising a large technology company in relation to insurance products as financial products.
Advising superannuation fund trustees on regulatory requirements.
Advising one of Australia's major retail banks with its financial planning dealer group and private wealth regulatory compliance.
Reviewing Product Disclosure Statements for fund managers including to address ASIC's disclosure benchmark requirements.